Drugs that contain Solriamfetol Hydrochloride
1. List of Sunosi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8877806 | JAZZ | Treatment of sleep-wake disorders |
Jun, 2026
(3 years from now) | |
| US9604917 | JAZZ | Treatment of sleep-wake disorders |
Jun, 2026
(3 years from now) | |
| US10351517 | JAZZ | Treatment of sleep-wake disorders |
Jun, 2026
(3 years from now) | |
| US8440715 | JAZZ | Treatment of sleep-wake disorders |
Aug, 2027
(4 years from now) | |
| US10512609 | JAZZ | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(14 years from now) | |
| US10195151 | JAZZ | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(14 years from now) | |
| US10912754 | JAZZ | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(15 years from now) | |
| US10959976 | JAZZ | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(15 years from now) | |
| US10940133 | JAZZ | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(17 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity (ODE) | Jun 17, 2026 |
NCE-1 date: June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa); Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in an adult through a dosing regimen that includes oral administration of 75 mg once daily for at least 3 days followed by 150 mg once daily; To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa) with a dosing regimen that includes a dose of 75 mg once daily for at least 3 days followed by 150 mg once daily; Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in a patient with moderate renal impairment
Dosage: TABLET;ORAL
2. List of Sunosi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11439597 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Nov, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity (ODE) | Jun 17, 2026 |
NCE-1 date: June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: NA
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic